Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Commit to this schedule and resist the urge to escalate doses faster than prescribed
J Berry Res
COA / Lab results Evidence: Clinical trial Pros Triple GLP-1 / GIP / glucagon agonism in one peptide raises energy expenditure, not appetite alone Largest weight reduction reported for an incretin-class compound (~24% at 12 mg, 48-wk phase 2) Reductions in HbA1c, visceral fat and liver-fat content across trials Once-weekly subcutaneous dosing (albumin-bound half-life) Cons GI effects require gradual multi-week dose titration Newest of the GLP-1 class phase 3 (TRIUMPH) topline only
Compensated cirrhosis Patients with MASH-related compensated cirrhosis (Child-Pugh A) represent a clinically important subgroup given the risk of hepatic decompensation and HCC
US$ 26.76
US$ 20.11
US$ 22.88
US$ 20.18
US$ 23.87
